R Tech

The FDA Has Approved R-Tech Ueno's Novel Ophthalmic Solution
May 23, 2013
The FDA has approved R-Tech Ueno's novel ophthalmic solution, developed using Novozymes Biopharma's recombinant human albumin, to enter into Phase I/II trials. R-Tech is trialing RU-101 ophthalmic solution as a severe dry eye therapy. ...

Tags: Ophthalmic Solution, Phase I/II Trials
R-Tech Ueno Has Begun Enrolling Patients with Severe Dry Eye
May 22, 2013
R-Tech Ueno has begun enrolling patients with severe dry eye in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in US. The two-stage trial is performed as a double masking test ...

Tags: R-Tech, Dry Eye Study
Lilly Gains an Additional Six Months of Us Market Exclusivity for Cymbalta
Jul 9, 2012
The International Court of Arbitration, International Chamber of Commerce (ICC), has issued its arbitral award in the arbitration filed by R-Tech Ueno, together with Sucampo Pharmaceuticals and Sucampo, against Takeda Pharmaceutical ...

Tags: arbitration, amitiza capsule, business